Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+B-cell lymphomas: Results from the SEXIE-R-CHOP-14 trial of the DSHNHL.

被引：8

作者：

Pfreundschuh, Michael

Held, Gerhard

Zeynalova, Samira

Zwick, Carsten

Haenel, Mathias

Truemper, Lorenz

Dreyling, Martin H.

Dierlamm, Judith

Loeffler, Markus

Schmitz, Norbert

Murawski, Niels

机构：

[1] Saarland Univ Med Sch, Homburg, Germany

[2] Univ Leipzig, Inst Med Informat Stat & Epidemiol, D-04109 Leipzig, Germany

[3] Chemnitz Hosp, Chemnitz, Germany

[4] Univ Med Goettingen, Gottingen, Germany

[5] Univ Hosp Grosshadern, Munich, Germany

[6] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[7] Asklepios Hosp St Georg, Hamburg, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.8501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8501

引用

页数：1

共 48 条

[31] Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial
Sawalha, Yazeed
Welkie, Rina Li
Krivenko, Anna
Hess, Brian
Sigmund, Audrey M.
Voorhees, Timothy
Hanel, Walter
Bond, David A.
Reneau, John C.
Epperla, Narendranath
Alinari, Lapo
Brammer, Jonathan E.
Christian, Beth
Baiocchi, Robert
Maddocks, Kami J.
BLOOD, 2023, 142
[32] Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study In Treatment-Naive Patients With CD20-Positive B-Cell Non-Hodgkin's Lymphoma (NHL)
Younes, Anas
Flinn, Ian
Berdeja, Jesus
Friedberg, Jonathan W.
Casulo, Carla
Thieblemont, Catherine
Morschhauser, Franck
Westin, Jason R.
Seetharam, Shobha
Hellemans, Peter
Smit, Hans
de Vries, Ronald
Dauphinee, Elisa
Badamo-Dotzis, Julie
Fourneau, Nele
Oki, Yasuhiro
BLOOD, 2013, 122 (21)
[33] Dose adjusted EPOCH chemotherapy plus rituximab combination (DA-R-EPOCH), an effective upfront therapy for patients with poor-risk aggressive B-cell lymphomas.: Results of a pilot study in a single center.
López, A
Gallur, L
Palacios, A
Navarrete, M
Ruiz-Marcellán, C
Castellví, J
Cajal, SRY
Juliá, A
BLOOD, 2005, 106 (11) : 259B - 259B
[34] Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial
Belada, David
Christensen, Jacob Haaber
Drott, Kristina
Snauwaert, Sylvia
Brody, Joshua
Narkhede, Mayur
Offner, Fritz
Elliot, Brian
Liu, Tracy
Stirner, Mariana Cota
Abbas, Aqeel
Falchi, Lorenzo
Clausen, Michael Roost
BLOOD, 2021, 138
[35] CONVENTIONAL CHEMOIMMUNOTHERAPY (R-CHOEP-14) OR HIGH-DOSE THERAPY (R-MEGA-CHOEP) FOR YOUNG, HIGH-RISK PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: FINAL RESULTS OF THE RANDOMIZED MEGA-CHOEP-TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP (DSHNHL)
Schmitz, N.
Nickelsen, M.
Ziepert, M.
Borchmann, P.
Nickenig, C.
Viardot, A.
Bentz, M.
Truemper, L.
Loeffler, M.
Pfreundschuh, M.
Glass, B.
ANNALS OF ONCOLOGY, 2011, 22 : 106 - 107
[36] Peg-filgrastim (Peg-F) on day 4 of (R-)CHOP-14 chemotherapy compared to day 2 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of a randomized trial of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL)
Hartmann, F.
Zeynalova, S.
Nickenig, C.
Reiser, M.
Lengfelder, E.
Duerk, H.
de Witt, M.
Schubert, J.
Loeffler, M.
Pfreundschuh, M. G.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[37] Peg-filgrastim (PEG-F) on day 4 of (R-)CHOP-14 chemotherapy is superior to day 2 in elderly patients with diffuse large B-cell-lymphoma (DLBCL):: Results of a randomized trial of the German high-grade non-Hodgkin-lymphoma study group (DSHNHL)
Poeschel, V.
Hartmann, F.
Zeynalova, S.
Nickenig, C.
Reiser, M.
Lengfelder, E.
Duerk, H.
Murawski, N.
Schubert, J.
Loeffler, M.
Pfreundschuh, M.
ANNALS OF ONCOLOGY, 2008, 19 : 149 - 149
[38] Final Results of a Phase II Danish Trial Testing Low Dose Total Body Irradiation Following Six Bi-Weekly RCHOP-14 Plus 2 Extra Rituximab in Elderly High risk Patients with Aggressive CD20+Diffuse Large B-Cell Lymphoma (DLBCL).
Safwat, Akmal
Specht, Lena
Hansen, Flemming
Hansen, Mads
Jurlander, Jesper
d'Amore, Francesco
BLOOD, 2008, 112 (11) : 372 - 373
[39] Six, not eight cycles of bi-weekly CHOP with rituximab (RCHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL).
Pfreundschuh, M
Kloess, M
Schmits, R
Zeynalova, S
Lengfelder, E
Franke, A
Steinhauer, H
Reiser, M
Clemens, M
Nickenig, C
de Wit, M
Hoffmann, M
Mertelsmann, R
Metzner, B
Ho, A
Truemper, L
Eimermacher, H
Mergenthaler, H
Liersch, R
Duehrsen, U
Balleisen, L
Hartmann, F
Poeschel, V
Schmitz, N
Loeffler, M
BLOOD, 2005, 106 (11) : 9A - 9A
[40] Six vs. eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the completed RICOVER-60 trial of the german high-grade non-Hodgkin lymphoma study group (DSHNHL).
Pfreundschuh, Michael
Kloess, Marita
Zeynalova, Samira
Lengfelder, Eva
Franke, Astrid
Reiser, Marcel
Steinhauer, Hjalmar
Clemens, Michael
Nickenig, Christina
de Wit, Maike
Metzner, Bernd
Hensel, Manfred
Mergenthaler, Hans-Guenther
Liersch, Ruediger
Duehrsen, Ulrich
Balleisen, Leopold
Engelhardt, Monika
Poeschel, Viola
Schubert, Joerg
Truemper, Lorenz
Schmitz, Norbert
Loeffler, Markus
BLOOD, 2006, 108 (11) : 64A - 65A

← 1 2 3 4 5 →